Overview

This trial is active, not recruiting.

Condition metastatic breast cancer
Treatment ezn-2208
Phase phase 2
Sponsor Enzon Pharmaceuticals, Inc.
Start date November 2009
End date February 2012
Trial size 160 participants
Trial identifier NCT01036113, EZN-2208-03

Summary

This is a Phase 2, multicenter, open-label, noncomparative study to evaluate safety,efficacy and of single-agent EZN 2208 administered in patients with previously treated MBC.

After discontinuation of study treatment, patients will receive care as considered appropriate by the investigator. Patients will continue to be followed for disease progression, subsequent anticancer therapy, and survival.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Experimental: EZN-2208 EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
ezn-2208 Peg SN38
EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.

Primary Outcomes

Measure
Response Rate
time frame: 2011

Secondary Outcomes

Measure
Progression Free Survival (PFS)
time frame: 2011

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Histologically confirmed breast adenocarcinoma that is metastatic. Receptor status of the tumor must be known. - Disease progression during or after immediate previous therapy, or intolerable toxicity leading to cessation of immediate previous therapy - Previous treatment for MBC: - AT Cohort: Prior AT required as adjuvant or metastatic therapy; no more than 2 prior chemotherapy regimens for MBC. - ATX Cohort: Prior ATX required as adjuvant or metastatic therapy;no more than 4 prior chemotherapy regimens for MBC. - For patients with positive receptor status: - Patients with HER2+ MBC must have received prior trastuzumab. - Patients with ER+ MBC must have received prior hormone therapy. - Measurable disease by RECIST Version 1.1 - Women 18 years or older - ECOG performance status of 0 to 2 - Adequate bone marrow, renal and hepatic functions Exclusion Criteria: - Major surgery within 3 weeks before study start - Known or suspected brain metastases requiring intervention with steroids and/or radiation therapy - Prior chemotherapy, immunotherapy, non-investigational agent, or other therapy used to treat the cancer within 3 weeks before scheduled administration of EZN-2208 - History of other primary cancer within 5 years of enrollment, unless 1. Curatively resected non-melanomatous skin cancer, or 2. Curatively resected cervical cancer - Lack of recovery to Grade 1 from any reversible side effects related to the administration of an investigational agent, chemotherapy, or other prior treatments for the cancer - Current participation in another clinical study with an investigational agent and/or use of an investigational drug (not including investigational use of an approved drug) in the 30 days before the first administration of EZN-2208 - Known chronic infectious disease, such as AIDS

Additional Information

Official title A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Principal investigator Joyce A O'Shaughnessy, MD
Description EZN-2208 will be administered by i.v. infusion weekly for 3 weeks in 4-week cycles. Study treatment will be continued until evidence of disease progression, unacceptable toxicity, or withdrawal of the patient's consent for participation in the study. Approximately 160 patients with previously treated MBC will be enrolled in this study. Eighty patients in each of two cohorts will be evaluated as follows: 1. AT Cohort - Patients treated with prior anthracycline and taxane as adjuvant or metastatic therapy; no more than 2 prior chemotherapy regimens for MBC 2. ATX Cohort - Patients treated with prior anthracycline, taxane, and Xeloda® (capecitabine) as adjuvant or metastatic therapy; no more than 4 prior chemotherapy regimens for MBC After discontinuation of study treatment, patients will receive care as considered appropriate by the investigator. Patients will continue to be followed for disease progression, subsequent anticancer therapy, and survival for at least 6 months after enrollment of the last patient in the study
Trial information was received from ClinicalTrials.gov and was last updated in October 2012.
Information provided to ClinicalTrials.gov by Enzon Pharmaceuticals, Inc..